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Somatostatin (SST)b exerts diverse biological actions through a family of five cell
surface SSTreceptors (SSTR) subtypes. These can be categorized into two subgroups, one
consisting of SSTRs 2,3 and 5 and the other made up of SSTRs 1 and 4 on the basis of
their ability orinability to bind octa- andhexa- peptide SST analogs [1, 2]. SST influences
multiple second messenger systems including adenylyl cyclase-cAMP, Ca2+, K+, protein
tyrosine phosphatase (PTP), protein serine phosphatase, mitogen activated protein kinase
and Na+/H+ antiporter, and exerts an inhibitory effect on hormone secretion, cell growth
and proliferation (reviewed in [1-3]). SST-induced inhibition ofcell proliferation can elic-
it either cytostatic (growth arrest) as well as cytotoxic (apoptosis) in tumor cells which
express multiple SSTR subtypes [4-9]. We have shown that SSTR mediatedcytotoxic sig-
naling in MCF-7 breast cancer cells involves rapid recruitment of the src homology 2
domain containing tyrosine phosphatase SHP-1, is associated with the induction of the
wild type (wt) tumor suppressor protein p53, the proapoptotic protein Bax and a cation-
insensitive acidic endonuclease [9, 10]. The mechanism underlying its cytostatic signal-
ing reported to occur in other tumor cells such as GH3 cells has not been elucidated.
Molecular mediators that regulate cytotoxic and cytostatic events include the tumor
suppressor protein p53, the cyclin dependent kinase inhibitorp2lWAFl/CIPl, the retinoblas-
toma protein pRB and the protooncogene product c-Myc. p53 can induce GI cell cycle
arrest via p2lWAFl/CIPI in the presence of growth factors or trigger apoptosis by inducing
Bax in the absence ofmitogenic signals [11-13]. Both these actions ofp53 are dependent
on its ability to acquire wtconformation in a mannerrequiring dephosphorylation ofphos-
phoserine residues [14]. c-Myc, like p53, can also induce eitherG1 arrest orapoptosis and
moreover, can abrogate p2lwAFl/cIPl induced G1 arrest [15]. pRB in its hypophosphory-
lated form induces G, cell cycle arrest independent ofp53 [16]. In order to determine if
SST influences these mediators in a SSTR subtype selective manner to differentially reg-
ulate cell cycle progression and apoptosis we set out to elucidate human (h) SSTR sub-
type selectivity for cytotoxic and cytostatic signaling and demonstrated that SST-induced
apoptosis is signaled uniquely via hSSTR3 whereas the other hSSTR subtypes signalG,
cell cycle arrest without inducing apoptosis [17, 18]. Here I summarize current evidence
demonstrating that SST elicits cytotoxic action uniquely via hSSTR3 in a p53 dependent
manner whereas its cytostatic action is exerted through other subtypes involving induction
ofpRB in a p53-independent manner.
We first assessed the subtype selectivity forregulating cellcycle inCHO-Ki cells sta-
bly expressing individual hSSTRs. Cells were treated with 100 nM OCT (hSSTRs 2,3,5)
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or D-Trp8 SST-14 (hSSTRs 1,4) for 24 hr, the DNA was stained with the intercalating dye
propidium iodide (PI) and analyzed by flow cytometry. The proliferative index was esti-
mated fromtheratio ofpopulations ofcells inGI and S phases (Figure 1). In cells express-
ing hSSTR3, OCT induced a decrease inGI and an increase in S phase indicating that it
triggered cell cycle progression via this subtype. By contrast, cells expressing other SSTR
subtypes responded with decreased cell proliferation, with the percentage ofcells increas-
ing in G1 relative to S demonstrating that hSSTRs 1,2,4 and 5 signal G1 cell cycle arrest.
Such cytostatic signaling was associated with the induction of pRB
(hSSTR5>hSSTR2>hSSTTR4>hSSTR1) (Figure 2). The cytotoxic signaling via hSSTR3
as well as the cytostatic signaling through the other hSSTRs was pertussis toxin sensitive
G protein dependent and was mediated by orthovanadate sensitive PTP [17]
In CHO-KI cells expressing hSSTR3 the antiproliferative action of OCT led to the
induction of wt p53 and apoptosis. The activity of tumor suppressor protein p53 is regu-
lated by Serphosphorylation. p53 is believed to be in an inactive conformation in its phos-
phorylated form and assumes its active conformation upon dephosphorylation of Ser
residues [14]. These forms can be distinguished by using epitope-specific anti-p53 anti-
bodies pAb 240 and pAb 1801: only the inactive form of(or mutant) p53 is recognized by
pAb 240, whereas both the inactive and active forms bind to pAb 1801. The results sum-
marized in Figure 3 show that OCT induces a 10-fold increase in wt p53 in its active con-
formation detected with pAb 1801 in CHO-KL cells expressing hSSTR3, but not other
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Figure 1. hSSTR subtype selective regulation of cell cycle progression in CHO-Kl cells.
Proliferative index was calculated from ratio ofcells in Gl and S phase in following treatment
with 100 nM OCT (hSSTRs 2,3,5) or D-Trp8 SST-14 (hSSTRs 1,4) for 24 hr. The change in
GI/S ratio in the treated cells is expressed relative to the G1/S ratios of the corresponding untreat-
ed cells taken as 1. OCT treatment elicited selective proliferative response in hSSTR3 expressing
cells as evidenced by the striking decrease in GI/ S ratio. By contrast, the increase in GI/S ratios in
cells expressing other four hSSTRs indicates that peptide treatment elicits cytostatic response
through these subtypes.Srikant: Somatostatin receptors and cytotoxic and cytostatic signaling
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Figure 2. Gl cell cycle arrest signaled via hSSTRs 1,2,4 and 5 in CHO-Kl cells is associated
with induction ofpRB. Values represent increase in fluorescence intensity ofpRB labeled with anti
pRB antibody and FITC conjugated second antibody. Results are expressed as increase in fluores-
cence relative to that in the respective untreated cells taken as 1 (mean + SE, n = 4).
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Figure 3. hSSTR subtype selective induction of wt p53. Increase in p53 detected by wt specific
anti- p53 antibody pAb 1801 is selectively signaled via hSSTR3 in CHO-Kl cells. pAb 1801
immunoreactive p53 was counterstained with FITC conjugated second antibody and quanti-
tated by flow cytometry. Results are expressed as increase in fluorescence relative to that in the
respective untreated cells taken as 1 (mean + SE, n = 4).
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Figure 4. Bivariate analysis ofhSSTR3 expressing CHO-Kl cells dual labeled with pAb 1801
(wt p53) and propidium iodide (DNA). OCT (100 nM) induced increase in wt p53 occurs in all
phases ofthe cell cycle. Additionally, the correlation between induction ofwt p53 and apoptosis is
seen from the increase in this tumor suppressor protein in cells with hypodiploid DNA content in
theAO region.
hSSTRs. By contrast, no change was observed in p53 recognized by the mutant-specific
anti-p53 antibody pAb 240 as described in detail previously by us [17].
Analysis of cells dual labeled with pAb 1801 and PI revealed that hSSTR3 signaled
increase in wtp53 occurs in all phases ofthe cell cycle during treatment with OCT for 96
hr (Figure 4). Bivariate analysis of dual labeled cells depicted as 3-D Isocontour plots
illustrate the decrease in G1 with concomitant accumulation of cells with hypodiploid
DNA content in the region marked AO. The presence of subdiploid DNA peak is a hall-
mark for apoptosis. That OCT induces apoptosis in hSSTR3 expressing cells in a time-
dependent manner was confirmed by the detection of oligonucleosome sized DNA frag-
ments by inversion field gel electrophoresis [17].
wtp53 is known to trigger either G1 arrest or apoptosis. hSSTR3 initiated increase in
p53 did not cause G1 cell cycle arrest. In support of this is our finding that OCT did not
influence either p21wAFl/cIPl (required for p53-induced GI arrest) or c-Myc (needed for
abrogating p21wAFl/cIP1 mediated GI arrest) in these cells [17]. We have shown that
hSSTR3 mediated induction of wtp53 occurs within minutes, increases in a time-depen-
dent manner and precedes the induction of Bax and the onset of apoptosis [17].
Furthermore, p53 exhibits perinuclear localization in untreated cells but display preferen-
tial intranuclear accumulation concomitant with nuclear shrinkage, acharacteristic feature
ofcells undergoing apoptosis [17].Srikant: Somatostatin receptors and cytotoxic and cytostatic signaling
Based on these findings, I propose the following mechanistic model ofhSSTR3 ini-
tiated cytotoxic signaling (Figure 5). The first event in this signal cascade is theregulation
of a SST-sensitive PTP in a G protein dependent manner. The principal mediator ofcyto-
toxic signaling initiated through hSSTR3 is wt p53 in its active conformation. A rapid,
time-dependent increase in wt p53 and its nuclear translocation occurs in OCT-treated
cells and precedes the onset of apoptosis. This, in turn, leads to the activation ofBax and
acidic endonuclease, thereby causing oligonucleosomal DNA fragmentation and apopto-
sis. The nuclear accumulation of wt p53 parallels nuclear shrinking, a characteristic fea-
ture of apoptosis. The increased pAb 1801 immunoreactive wt p53 as well as its activa-
tion are dependent on dephosphorylation of Ser residues suggesting that by hSSTR3
linked PTP may activate SerlThr phosphatase(s) [14, 17]. SST-sensitive PTP has been
implicated in attenuating growth factor receptor kinase induced mitogenic signaling [19,
20]. Inhibition ofmitogenic signaling viahSSTR3 may, therefore, be conducive forinduc-
tion of wt p53 dependent apoptosis. PTP dependent antiproliferative signaling through
other SSTR subtypes may lead to Gi arrest since these do not induce either wt p53 or
SST
hSSTR 3
PTP
Ser/Thr
phosphatases
wt p53
Inactive * active
Bax
Acidic Endonuclease
Apoptosis
Figure 5. Proposed mechanism ofhSSTR3 selective cytotoxic signaling.
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apoptosis. This raises the question of whether hSSTR3 and other SSTR subtypes signal
through different PTPs. We have recently reported that membrane associated PTP is not
directly activated in tumor cells, contradicting previous claims [10, 19, 20]. We demon-
strated that a net increase in membrane-associated PTP occurs in MCF-7 breast cancer
cells preincubated with OCT and, additionally, have identified SHP-1
(PTPIC/SHPTP1I/HCP/ SHP) as the intracellular PTP recruited by OCT in a time- and
concentration-dependent manner [10]. Studies are in progress to delineate the role of
SHP-1 in subtype-selective hSSTR-mediated cytotoxic and cytostatic signaling.
We have shown that OCT induced cytotoxic signaling in MCF-7 cells occurs in ap53
dependent manner, requiring the downstream induction of Bax and cation-insensitive
acidic endonuclease [9]. Surprisingly, the rate of cytotoxic signaling was faster in MCF-7
cells compared to CHO-KI cells expressing hSSTR3 [9]. The rapidity of OCT induced
cytotoxic signaling in MCF-7 cells may be due to higher levels of SHP-1 and/or wt p53
compared to CHO-KI cells. Our findings suggest, but does not prove, that the cytotoxic
signaling of OCT in this cell line is signaled via hSSTR3 subtype. This contradicts the
reported absence of SSTR3 transcripts in MCF-7 cells by RT-PCR analysis [21]. Studies
are currently in progress to resolve this issue. Ifthis is confirmed at the protein level, then
the potential existence of a novel SSTR subtype that is functionally similar to hSSTR3
should be considered, since the other known hSSTR subtypes do not activate the apoptot-
ic pathway. In contrast to the cytotoxic effects documented in MCF-7 and AtT-20 cells,
SST is reported to elicit only cytostatic effect in GH3 cells which do express SSTR3 [7-9,
22]. This may be due to functional differences between human and rat SSTR3 or, alterna-
tively, due to mutation in the p53 molecule may render it incapable ofassuming the active
conformation in GH3 cells.
Overexpression of Bax has been shown to sensitize MCF-7 cells to radiation [23].
Agonist-dependent SSTR internalization has been observed in tumor cells and is reported
to occur maximally via hSSTR3 [24, 25]. The selectivity of hSSTR3 for inducing Bax in
wtp53-dependent manner, combined with its ability to sequester the ligand within the cell,
provides a rational basis forexploiting the therapeutic potential ofa- and ,B- emitting OCT
tagged radionuclides such as "'In, 99Tc, 67/68Ga and 161Tb in the treatment of tumors
expressing hSSTR3 and wtp53. Such compounds are already in use for scintigraphic visu-
alization of SSTR-positive tumors [26-29].
Tamoxifen potentiates the cytotoxic activity of OCT in two estrogen-responsive cell
lines MCF-7, T47-D and ZR-75-1 (Sharma and Srikant, unpublished observations). A
positive influence of OCT enhancing the antineoplastic effect of tamoxifen and ovariec-
tomy has also been reported in vivo on 7,12-dimethylbenzanthracene-induced mammary
carcinoma [30]. Its cytotoxic and/or cytostatic activity in vivo is difficult to assess since
SST exerts growth inhibitory action indirectly also by decreasing growth factor (e.g., IGF-
1) bioavailability, [31, 32].
In summary, cytotoxic signaling of SST resulting in apoptosis is selectively trans-
duced through hSSTR3. Such cytotoxic signaling requires dephosphorylation dependent
conformational change and activation of wt p53, and its rapid nuclear translocation fol-
lowed by induction of Bax and acidic endonuclease. These events occur in cells actively
traversing the cell cycle. Since hSSTR3 bound agonist is maximally intemalized, Ipredict
that a- and I- emitting OCT-tagged radionuclides will be most useful in treating tumors
expressing hSSTR3 and wt p53, not only because of receptor mediated cytotoxic signal-
ing, but also due to greater sensitization by hormonally induced Bax to radiation damage
by internalized radioactivity as a consequence ofreceptor-mediated endocytosis.
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